干扰素β治疗的多发性硬化症患者中抗干扰素β结合抗体的检测：给临床医生和基础科学家的启示 - Suppr | 超能文献

Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist.

作者信息

Pachner Andrew R

出版信息

J Neuroimmunol. 2008 Feb;194(1-2):5-6. doi: 10.1016/j.jneuroim.2007.10.015. Epub 2007 Nov 26.

DOI:10.1016/j.jneuroim.2007.10.015

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist.干扰素β治疗的多发性硬化症患者中抗干扰素β结合抗体的检测：给临床医生和基础科学家的启示

J Neuroimmunol. 2008 Feb;194(1-2):5-6. doi: 10.1016/j.jneuroim.2007.10.015. Epub 2007 Nov 26.

2

Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies.

J Neuroimmunol. 2006 May;174(1-2):174-9. doi: 10.1016/j.jneuroim.2006.01.017. Epub 2006 Mar 23.

3

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.多发性硬化症患者中干扰素β中和抗体的检测

J Neurol. 2004 Jun;251 Suppl 2:II31-9. doi: 10.1007/s00415-004-1206-5.

4

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.中和抗体的持久性取决于效价和干扰素-β制剂。

Mult Scler. 2012 May;18(5):610-5. doi: 10.1177/1352458511426738. Epub 2011 Oct 19.

5

Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.抗干扰素-β中和活性并非完全由抗体介导。

J Neuroimmunol. 2007 Dec;192(1-2):198-205. doi: 10.1016/j.jneuroim.2007.09.025. Epub 2007 Oct 22.

6

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.一种基于实时PCR的生物测定法的开发与验证，用于定量检测抗人干扰素-β的中和抗体。

J Immunol Methods. 2007 Apr 10;321(1-2):19-31. doi: 10.1016/j.jim.2006.12.012. Epub 2007 Feb 20.

7

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.测量干扰素β生物活性的重要性：对多发性硬化症患者的监测及抗干扰素β抗体的影响

J Neuroimmunol. 2005 Sep;166(1-2):180-8. doi: 10.1016/j.jneuroim.2005.06.003.

8

Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.用于治疗多发性硬化症患者的β-干扰素制剂在中和抗体血清阳性率和免疫原性方面存在差异。

Mult Scler. 2007 Mar;13(2):208-14. doi: 10.1177/1352458506070762. Epub 2007 Jan 29.

9

Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.多发性硬化症中针对干扰素β的中和抗体：细胞病变效应测定法验证的分析评估

Clin Chim Acta. 2007 Feb;377(1-2):185-91. doi: 10.1016/j.cca.2006.09.021. Epub 2006 Sep 30.

10

Neutralising antibodies against interferon beta in multiple sclerosis.多发性硬化症中针对β干扰素的中和抗体。

Lancet. 2004 Jan 10;363(9403):168; author reply 168-9. doi: 10.1016/S0140-6736(03)15277-4.

引用本文的文献

1

Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.接受重组人干扰素α-2a治疗的白塞病葡萄膜炎患者中的抗干扰素α抗体和自身抗体。

Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):457-65. doi: 10.1007/s00417-014-2856-3. Epub 2014 Dec 12.